PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Cancer Research

Volumn 60, Issue 8, 2000, Pages 2178-2189

  Wood, Jeanette M ^a   Bold, Guido ^a   Buchdunger, Elizabeth ^a   Cozens, Robert ^a   Ferrari, Stefano ^a   Frei, Jörg ^a   Hofmann, Francesco ^a   Mestan, Jürgen ^a   Mett, Helmut ^a   O'Reilly, Terence ^a   Persohn, Elke ^a   Rösel, Johannes ^a   Schnell, Christian ^a   Stover, David ^a   Theuer, Andreas ^a   Towbin, Harry ^a   Wenger, Fritz ^a   Woods Cook, Kathie ^a   Menrad, Andreas ^b   Siemeister, Gerhard ^b   Schirner, Michael ^b   Thierauch, Karl Heinz ^b   Schneider, Martin R ^b   Drevs, Joachim ^c   Martiny Baron, Georg ^c   Totzke, Frank ^c   Marmé, Dieter ^c   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b BAYER PHARMA AG   (Germany)

^c TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

[1 [4 CHLOROANILINO] 4 [4 PYRIDYLMETHYL] PHTHALAZINE SUCCINATE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; HEMATOPOIESIS; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE MARROW CELLS; CARCINOMA; CELL DIVISION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HEMATOPOIESIS; HUMANS; KIDNEY NEOPLASMS; LEUKOCYTES; LYMPHOKINES; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PHTHALAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; WOUND HEALING;

EID: 0034655182     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Taichman, N. S., Young, S., Cruchley, A. T., Taylor, P., and Paleolog, E. Human neutrophils secrete vascular endothelial growth factor. J. Leukocyte Biol., 62: 397-400, 1997.
2. Horiuchi, T., and Weller, P. F. Expression of vascular endothelial growth factor by human eosinophils: up-regulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am. J. Respir. Cell Mol. Biol., 17: 70-77, 1997.
3. Amano, S., Rohan, R., Kuroki, M., Tolentino, M., and Adamis, A. P. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neo vascularization. Investig. Ophthalmol. Vis. Sci., 39: 18-22, 1998.
4. Griga, T., Tromm, A., Spranger, J., and May, B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand. J. Gastroenterol., 13: 504-508, 1998.
5. Fava, R. A., Olsen, N. J., Spencer, G. G., Yeo, K. T., Yeo, T. K., Berse, B., Jackman, R. W., Senger, D. R., Dvorak, H. F., and Brown, L. F. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med., 180: 341-346, 1994.
6. Nagashima, M., Yoshino, S., Ishiwata, T., and Asano, G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J. Rheumatol., 22: 1624-1630, 1995.
7. Paleolog, E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF α antibody in rheumatoid arthritis. Mol. Pathol., 50: 225-233, 1997.
8. Koch, A. E. Review. Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum., 41: 951-962, 1998.
9. Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., and Keshet, E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med., 1: 1024-1028, 1995.
10. Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L., and Smith, L. E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA, 92: 10457-10461, 1995.
11. Robinson, G. S., Pierce, E. A., Rook, S. L., Foley, E., Webb, R., and Smith, L. E. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. USA, 93: 4851-4856, 1996.
12. Vinores, S. A., Youssri, A. I., Luna, J. D., Chen, Y. S., Bhargave, S., Vinores, M. A., Schoenfeld, C. L., Peng, B., Chan, C. C., LaRochelle, W., Green, W. R., and Campochiaro, P. A. Up-regulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol., 12: 99-109, 1997.
13. Armstrong, D., Augustin, A. J., Spengler, R., Al, J. A., Nickola, T., Grus, F., and Koch, F. Detection of vascular endothelial growth factor and tumor necrosis factor α in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica, 212: 410-414, 1998.
14. Detmar, M., Brown, L. F., Claffey, K. P., Yeo, K. T., Kocher, O., Jackman, R. W., Berse, B., and Dvorak, H. F. Overexpression of vascular permeability factor/vascular endothelial growth factor and ils receptors in psoriasis. J. Exp. Med., 180: 1141-1146, 1994.
15. Weninger, W., Rendl, M., Mildner, M., and Tschachler, E. Retinoids down-regulate vascular endothelial growth factor/vascular permeability factor production by normal human keratinocytes. J. Investig. Dermatol., 111: 907-911, 1998.
16. Delmar, M., Brown, L. F., Schon, M. P., Elicker, B. M., Velasco, P., Richard, L., Fukumura, D., Monsky, W., Claffey, K. P., and Jain, R. K. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Investig. Dermatol., 111: 1-6, 1998.
17. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res., 53: 5822-5827, 1993.
18. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
19. Brown, L. F., Detmar, M., Claffey, K., Nagy, J. A.,. Feng, D., Dvorak, A. M., and Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Exper. Suppl. (Basel), 79: 233-269, 1997.
20. Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T., and Risau, W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol., 140: 947-959, 1998.
21. Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., and Sato, M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 5: 519-524, 1990.
22. Terman, B. I., Dougher, V. M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun., 187: 1579-1586, 1992.
23. Jakeman, L. B., Winer, J., Bennett, G. L., Altar, C. A., and Ferrara, N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Investig., 89: 244-253, 1992.
24. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Serger, D. R., and Dvorak, H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 53: 4727-4735, 1993.
25. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., and Senger, D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143: 1255-1262, 1993.
26. Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., Orpana, A., Pettersson, R. F., Alitalo, K., and Eriksson, U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA, 93: 2576-2581, 1996.
27. Olofsson, B., Korpelainen, E., Pepper, M. S., Mandriota, S. J., Aase, K., Kumar, V., Gunji, Y., Jeltsch, M. M., Shibuya, M., Alitalo, K., and Eriksson, U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA, 95: 11709-11714, 1998.
28. Clauss, M., Weich, H., Breier, G., Knies, U., Rockl, W., Waltenberger, J., and Risau, W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem., 271: 17629-17634, 1996.
29. Park, J. E., Chen, H. H., Winer, J., Houck, K. A., and Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem., 269: 25646-25654, 1994.
30. Joukov, V., Kaipainen, A., Jeltsch, M., Pajusola, K., Olofsson, B., Kumar, V., Eriksson, U., and Alitalo, K. Vascular endothelial growth factors VEGF-B and VEGF-C. J. Cell. Physiol., 173: 211-215, 1997.
31. Yamada, Y., Nezu, J., Shimane, M., and Hirata, Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics, 42: 483-488, 1997.
32. Achen, M. G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A., Wilks, A. F., Alitalo, K., and Stacker, S. A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA, 95: 548-553, 1998.
33. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., and Alitalo, K. A novel vascular endothelial growth factor. VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases [published erratum appears in EMBO J., 15: 1751, 1996]. EMBO J., 15: 290-298, 1996.
34. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., and Alitalo, K. A novel vascular endothelial growth factor. VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases [published erratum appears in EMBO J., 15: 1751, 1996]. EMBO J., 15: 290-298, 1996.
35. Kukk, E., Lymboussaki, A., Taira, S., Kaipainen, A., Jeltsch, M., Joukov, V., and Alitalo, K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (Camb.), 122: 3829-3837, 1996.
36. Maru, Y., Yamaguchi, S., and Shibuya, M. Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials. Oncogene, 16: 2585-2595, 1998.
37. Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H., and Ferrara, N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J. Biol. Chem., 271: 5638-5646, 1996.
38. Waltenberger, J., Claesson, W. L., Siegbahn, A., Shibuya, M., and Heldin, C. H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem., 269: 26988-26995, 1994.
39. Barleon, B., Sozzani, S., Zhou, D., Weich, H. A., Mantovani, A., and Marme, D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood, 87: 3336-3343, 1996.
40. Takahashi, T., and Shibuya, M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene, 14: 2079-2089, 1997.
41. Kroll, J., and Waltenberger, J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem., 272: 32521-32527, 1997.
42. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (Lond.), 380: 435-439, 1996.
43. Ferrara, N., Carver, M. K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell, B. L., Hillan, K. J., and Moore, M. W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (Lond.), 380: 439-442, 1996.
44. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (Lond.), 376: 66-70, 1995.
45. Fong, G. H., Klingensmith, J., Wood, C. R., Rossant, J., and Breitman, M. L. Regulation of flt-1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium. Dev. Dyn., 207: 1-10, 1996.
46. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (Lond.), 376: 62-66, 1995.
47. Shalaby, F., Ho, J., Stanford, W. L., Fischer, K. D., Schuh, A. C., Schwartz, L., Bernstein, A., and Rossant, J. A requirement for Flk-1 in primitive and definitive hematopoiesis and vasculogenesis. Cell, 89: 981-990, 1997.
48. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
49. Presta, L. G., Chen, H., O'Conror, S. J., Chisholm, V., Meng, Y. G., Krummen, L., Winkler, M., and Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 57: 4593-4599, 1997.
50. Borgstrom, P., Hillan, K. J., Sriramarao, P., and Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res., 56: 4032-4039, 1996.
51. Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., and Bohlen, P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev., 17: 155-161, 1998.
52. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med., 3: 1222-1227, 1997.
53. Lin, P., Sankar, S., Shan, S., Dewhirst, M. W., Polverini, P. J., Quinn, T. Q., and Peters, K. G. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ., 9: 49-58, 1998.
54. Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., Thomas, K. A., and Curiel, D. T. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA, 95: 8795-8800, 1998.
55. Yoshiji, H., Harris, S. R., and Thorgeirsson, U. P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res., 57: 3924-3928, 1997.
56. Benjamin, L. E., and Keshet, E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA, 94: 8761-8766, 1997.
57. Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., and Strawn, L. M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res., 56: 1615-1620, 1996.
58. Shibuya, M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res., 67: 281-316, 1995.
59. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., and Ellis, L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res., 55: 3964-3968, 1995.
60. Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Keri, O., Orfi, L., Risau, W., Flamme, I., Ullrich, A., Hirth, K. P., and Shawver, L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.
61. Fong, T. A. T., Shawver, L. K. Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R. Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
62. Wood, J., Buchdunger, E., Cozens, R., Hofmann, F., Mestan, J., Mett, H., Müller, M., Roesel, J., Schnell, C., Stover, D., Woods-Cook, K., Bold, G., Frei, J., Towbin, H., Kotyuk, B., Sills, M., Wass, K., Schirner, M., Schneider, M., Martiny-Baron, G., Siemeister, G., Totzke, F., and Marme, D. Pharmacological profile of a potent and orally active inhibitor of VEGF receptor tyrosine kinases. Proc. Am. Assoc. Cancer Res., 39: 96, 1998.
63. Bold, G., Altmann, K-H., Brüggen, J., Frei, J., Lang, M., Manley, P. W., Traxler, P., Wietfeld, B., Buchdunger, E., Cozens, R., Ferrari, S., Furel, P., Hofmann, F., Martiny-Baron, G., Mestan, J., Rösel, J., Sills, M., Stover, D., Acemoglu, F., Boss, E., Emmengger, R., Lässer, L., Masso, E., Roth, R., Schlachter, C., Vetterli, W., Wyss, D., and Wood, J. M. New anilino-phthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor driven angiogenesis. J. Med. Chem., in press, 2000.
64. Siemeister, G., Schnurr, B., Mohrs, K., Schachtele, C., Marmé, D., and Martiny-Baron, G. Expression of biologically active forms of the tumor angiogenesis factor VEGF in Escherichia coli. Biochem. Biophys. Res. Commun., 22: 249-255, 1996.
65. Nicosia, R. F., and Ottinetto, A. Growth of microvessels in serum free matrix culture of rat aorta: a quantitative assay of angiogenesis in vitro. Lab. Investig., 63: 115-122, 1990.
66. Schlaeppi, J. M., Siemeister, G., Weindel, K., Schnell, C., and Wood, J. Characterization of a new potent in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor. J. Cancer Res. Clin. Oncol., 125: 336-342, 1999.
67. Hoffmann, J., Schirner, M., Menrad, A., and Schneider, M. R. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res., 57: 3847-3851, 1997.
68. Yano, S., Herbst, R. S., Shinohara, H., Knighton, B., Bucana, C. D., Killion, J., Wood, J., and Fidler, I. J. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res., 6: 957-965, 2000.
69. Ozaki, H., Seo, M. S., Ozaki, K., Yamada, H., Yamada, E., Okamoto, N., Hofmann, F., Wood, J. M., and Campochiaro P. A. Blockade of VEGF signalling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol., 156: 697-707, 2000.
70. Yazaki, T., Takamiya, Y., Costello, P. C., Mineta, T., Menon, A. G., Rabkin, S. D., and Martuza, R. L. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J. Neuro-Oncol., 23: 23-29, 1995.
71. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
72. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
73. Takamiya, Y., Brem, H., Ojeifo, J., Mineta, T., and Martuza, R. L. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery (Baltimore), 34: 869-875, 1994.